Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells.

Ward NC, Yu A, Moro A, Ban Y, Chen X, Hsiung S, Keegan J, Arbanas JM, Loubeau M, Thankappan A, Yamniuk AP, Davis JH, Struthers M, Malek TR.

J Immunol. 2018 Nov 1;201(9):2579-2592. doi: 10.4049/jimmunol.1800907. Epub 2018 Oct 3.

PMID:
30282751
2.

A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines.

Zhao Q, Kim T, Pang J, Sun W, Yang X, Wang J, Song Y, Zhang H, Sun H, Rangan V, Deshpande S, Tang H, Cvijic ME, Westhouse R, Olah T, Xie J, Struthers M, Salter-Cid L.

J Leukoc Biol. 2017 Nov;102(5):1271-1280. doi: 10.1189/jlb.5A0717-302. Epub 2017 Sep 12.

PMID:
28899907
3.

Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.

Hoyt SB, Taylor J, London C, Ali A, Ujjainwalla F, Tata J, Struthers M, Cully D, Wisniewski T, Ren N, Bopp C, Sok A, Verras A, McMasters D, Chen Q, Tung E, Tang W, Salituro G, Clemas J, Zhou G, MacNeil D, Duffy R, Xiong Y.

Bioorg Med Chem Lett. 2017 Jun 1;27(11):2384-2388. doi: 10.1016/j.bmcl.2017.04.021. Epub 2017 Apr 8.

PMID:
28416132
4.

Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension.

Petrilli WL, Hoyt SB, London C, McMasters D, Verras A, Struthers M, Cully D, Wisniewski T, Ren N, Bopp C, Sok A, Chen Q, Li Y, Tung E, Tang W, Salituro G, Knemeyer I, Karanam B, Clemas J, Zhou G, Gibson J, Shipley CA, MacNeil DJ, Duffy R, Tata JR, Ujjainwalla F, Ali A, Xiong Y.

ACS Med Chem Lett. 2016 Nov 22;8(1):128-132. doi: 10.1021/acsmedchemlett.6b00455. eCollection 2017 Jan 12.

5.

Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder.

Harper BH, Wang L, Zhu C, Kar NF, Li B, Moyes CR, Goble SD, Costa M, Dingley K, Di Salvo J, Ha SN, Hurley A, Li X, Miller RR, Nagabukuro H, Salituro GM, Smith S, Struthers M, Hale JJ, Edmondson SD, Berger R.

Bioorg Med Chem Lett. 2017 Feb 15;27(4):1094-1098. doi: 10.1016/j.bmcl.2016.12.033. Epub 2016 Dec 11.

PMID:
28089699
6.

Imidazopyridyl compounds as aldosterone synthase inhibitors.

Whitehead BR, Lo MM, Ali A, Park MK, Hoyt SB, Xiong Y, Cai J, Carswell E, Cooke A, MacLean J, Ratcliffe P, Robinson J, Bennett DJ, Clemas JA, Wisniewski T, Struthers M, Cully D, MacNeil DJ.

Bioorg Med Chem Lett. 2017 Jan 15;27(2):143-146. doi: 10.1016/j.bmcl.2016.12.003. Epub 2016 Dec 2.

PMID:
27979595
7.

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, Gichuru L, Kulick A, Donnelly MJ, Jochnowitz N, Hurley AL, Pereira A, Sanfiz A, Veronin G, Villa K, Woods J, Zamlynny B, Zycband E, Salituro GM, Frenkl T, Weber AE, Edmondson SD, Struthers M.

J Pharmacol Exp Ther. 2017 Feb;360(2):346-355. doi: 10.1124/jpet.116.237313. Epub 2016 Dec 13.

PMID:
27965369
8.

Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.

Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, Berger R, Goble SD, Morriello G, Harper B, Moyes CR, Shen DM, Wang L, Ball R, Fitzmaurice A, Frenkl T, Gichuru LN, Ha S, Hurley AL, Jochnowitz N, Levorse D, Mistry S, Miller RR, Ormes J, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Green S, Struthers M, Weber AE.

J Med Chem. 2016 Jan 28;59(2):609-23. doi: 10.1021/acs.jmedchem.5b01372. Epub 2016 Jan 8.

PMID:
26709102
9.

Discovery of benzamides as potent human β3 adrenergic receptor agonists.

Zhu C, Kar NF, Li B, Costa M, Dingley KH, Di Salvo J, Ha SN, Hurley AL, Li X, Miller RR, Salituro GM, Struthers M, Weber AE, Hale JJ, Edmondson SD.

Bioorg Med Chem Lett. 2016 Jan 1;26(1):55-9. doi: 10.1016/j.bmcl.2015.11.030. Epub 2015 Nov 11.

PMID:
26590100
10.

Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Hoyt SB, Petrilli W, London C, Liang GB, Tata J, Hu Q, Yin L, van Koppen CJ, Hartmann RW, Struthers M, Wisniewski T, Ren N, Bopp C, Sok A, Cai TQ, Stribling S, Pai LY, Ma X, Metzger J, Verras A, McMasters D, Chen Q, Tung E, Tang W, Salituro G, Buist N, Clemas J, Zhou G, Gibson J, Maxwell CA, Lassman M, McLaughlin T, Castro-Perez J, Szeto D, Forrest G, Hajdu R, Rosenbach M, Xiong Y.

ACS Med Chem Lett. 2015 Jul 17;6(8):861-5. doi: 10.1021/acsmedchemlett.5b00048. eCollection 2015 Aug 13.

11.

The Avera Marshall decision. What the Supreme Court's ruling means for hospitals and physicians.

Struthers M, Knoedler T.

Minn Med. 2015 May;98(5):29-31. No abstract available.

PMID:
26065185
12.

Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity.

Mangan PR, Su LJ, Jenny V, Tatum AL, Picarillo C, Skala S, Ditto N, Lin Z, Yang X, Cotter PZ, Shuster DJ, Song Y, Borowski V, Thomas RL, Heimrich EM, Devaux B, Das Gupta R, Carvajal I, McIntyre KW, Xie J, Zhao Q, Struthers M, Salter-Cid LM.

J Pharmacol Exp Ther. 2015 Aug;354(2):152-65. doi: 10.1124/jpet.115.224246. Epub 2015 May 26.

PMID:
26015463
13.

Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Hoyt SB, Park MK, London C, Xiong Y, Tata J, Bennett DJ, Cooke A, Cai J, Carswell E, Robinson J, MacLean J, Brown L, Belshaw S, Clarkson TR, Liu K, Liang GB, Struthers M, Cully D, Wisniewski T, Ren N, Bopp C, Sok A, Cai TQ, Stribling S, Pai LY, Ma X, Metzger J, Verras A, McMasters D, Chen Q, Tung E, Tang W, Salituro G, Buist N, Kuethe J, Rivera N, Clemas J, Zhou G, Gibson J, Maxwell CA, Lassman M, McLaughlin T, Castro-Perez J, Szeto D, Forrest G, Hajdu R, Rosenbach M, Ali A.

ACS Med Chem Lett. 2015 Apr 7;6(5):573-8. doi: 10.1021/acsmedchemlett.5b00054. eCollection 2015 May 14.

14.

Inhibition of HCV translation by disrupting the structure and interactions of the viral CRE and 3' X-tail.

Tuplin A, Struthers M, Cook J, Bentley K, Evans DJ.

Nucleic Acids Res. 2015 Mar 11;43(5):2914-26. doi: 10.1093/nar/gkv142. Epub 2015 Feb 20.

15.

Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.

Cai TQ, Stribling S, Tong X, Xu L, Wisniewski T, Fontenot JA, Struthers M, Akinsanya KO.

J Pharmacol Toxicol Methods. 2015 Jan-Feb;71:137-46. doi: 10.1016/j.vascn.2014.09.011. Epub 2014 Oct 7.

PMID:
25304940
16.

Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder.

Moyes CR, Berger R, Goble SD, Harper B, Shen DM, Wang L, Bansal A, Brown PN, Chen AS, Dingley KH, Di Salvo J, Fitzmaurice A, Gichuru LN, Hurley AL, Jochnowitz N, Miller RR, Mistry S, Nagabukuro H, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Struthers M, Weber AE, Edmondson SD.

J Med Chem. 2014 Feb 27;57(4):1437-53. doi: 10.1021/jm4017224. Epub 2014 Feb 5.

PMID:
24437735
17.

The Sec1/Munc18 protein Vps45 regulates cellular levels of its SNARE binding partners Tlg2 and Snc2 in Saccharomyces cerevisiae.

Shanks SG, Carpp LN, Struthers MS, McCann RK, Bryant NJ.

PLoS One. 2012;7(11):e49628. doi: 10.1371/journal.pone.0049628. Epub 2012 Nov 14.

18.

A twist in the tail: SHAPE mapping of long-range interactions and structural rearrangements of RNA elements involved in HCV replication.

Tuplin A, Struthers M, Simmonds P, Evans DJ.

Nucleic Acids Res. 2012 Aug;40(14):6908-21. doi: 10.1093/nar/gks370. Epub 2012 May 4.

19.

Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.

Kandimalla ER, Struthers M, Bett AJ, Wisniewski T, Dubey SA, Jiang W, Precopio M, Sun Z, Wang H, Lan T, Agrawal S, Casimiro DR.

Cell Immunol. 2011;270(2):126-34. doi: 10.1016/j.cellimm.2011.03.027. Epub 2011 Apr 22.

PMID:
21570062
20.

Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists.

Morriello GJ, Wendt HR, Bansal A, Di Salvo J, Feighner S, He J, Hurley AL, Hreniuk DL, Salituro GM, Reddy MV, Galloway SM, McGettigan KK, Laws G, McKnight C, Doss GA, Tsou NN, Black RM, Morris J, Ball RG, Sanfiz AT, Streckfuss E, Struthers M, Edmondson SD.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1865-70. doi: 10.1016/j.bmcl.2010.12.087. Epub 2010 Dec 25.

PMID:
21353541
21.

Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation.

Jerath MR, Liu P, Struthers M, Demartino JA, Peng R, Peterson LB, Cumiskey AM, Yang L, Rojas M, Patel DD, Fong AM.

Thromb J. 2010 Sep 13;8:14. doi: 10.1186/1477-9560-8-14.

22.

CCR2 antagonists.

Struthers M, Pasternak A.

Curr Top Med Chem. 2010;10(13):1278-98. Review.

PMID:
20536421
23.

Synthesis and immunological activities of novel agonists of toll-like receptor 9.

Struthers M, Bett AJ, Wisniewski T, Dubey SA, Precopio M, Jiang W, Sun Z, Wang H, Nowak I, Putta MR, Yu D, Tang JX, Kandimalla ER, Agrawal S, Casimiro DR.

Cell Immunol. 2010;263(1):105-13. doi: 10.1016/j.cellimm.2010.03.005. Epub 2010 Mar 10.

PMID:
20381019
24.

Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles.

Goble SD, Wang L, Howell KL, Bansal A, Berger R, Brockunier L, DiSalvo J, Feighner S, Harper B, He J, Hurley A, Hreniuk D, Parmee E, Robbins M, Salituro G, Sanfiz A, Streckfuss E, Watkins E, Weber AE, Struthers M, Edmondson SD.

Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9. doi: 10.1016/j.bmcl.2010.01.130. Epub 2010 Feb 4.

PMID:
20181479
25.

Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist.

Wisniewski T, Bayne E, Flanagan J, Shao Q, Wnek R, Matheravidathu S, Fischer P, Forrest MJ, Peterson L, Song X, Yang L, Demartino JA, Struthers M.

J Immunol Methods. 2010 Jan 31;352(1-2):101-10. doi: 10.1016/j.jim.2009.10.010. Epub 2009 Nov 10.

PMID:
19913021
26.

Functional homology of mammalian syntaxin 16 and yeast Tlg2p reveals a conserved regulatory mechanism.

Struthers MS, Shanks SG, MacDonald C, Carpp LN, Drozdowska AM, Kioumourtzoglou D, Furgason ML, Munson M, Bryant NJ.

J Cell Sci. 2009 Jul 1;122(Pt 13):2292-9. doi: 10.1242/jcs.046441. Epub 2009 Jun 9.

27.

Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.

Kothandaraman S, Donnely KL, Butora G, Jiao R, Pasternak A, Morriello GJ, Goble SD, Zhou C, Mills SG, Maccoss M, Vicario PP, Ayala JM, Demartino JA, Struthers M, Cascieri MA, Yang L.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1830-4. doi: 10.1016/j.bmcl.2008.12.050. Epub 2008 Dec 24.

PMID:
19237282
28.

Reasons to be cautious about cholesterol lowering drugs.

Struthers M.

BMJ. 2008 Sep 3;337:a1493. doi: 10.1136/bmj.a1493. No abstract available.

PMID:
18768557
29.

A hepatitis C virus cis-acting replication element forms a long-range RNA-RNA interaction with upstream RNA sequences in NS5B.

Diviney S, Tuplin A, Struthers M, Armstrong V, Elliott RM, Simmonds P, Evans DJ.

J Virol. 2008 Sep;82(18):9008-22. doi: 10.1128/JVI.02326-07. Epub 2008 Jul 9.

30.

Conformational studies of 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists leading to new spirocyclic antagonists.

Pasternak A, Goble SD, Doss GA, Tsou NN, Butora G, Vicario PP, Ayala JM, Struthers M, Demartino JA, Mills SG, Yang L.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1374-7. doi: 10.1016/j.bmcl.2008.01.016. Epub 2008 Jan 9.

PMID:
18215519
31.

Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists.

Pasternak A, Goble SD, Vicario PP, Di Salvo J, Ayala JM, Struthers M, DeMartino JA, Mills SG, Yang L.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):994-8. doi: 10.1016/j.bmcl.2007.12.029. Epub 2007 Dec 27.

PMID:
18164199
32.

Cellular levels of the syntaxin Tlg2p are regulated by a single mode of binding to Vps45p.

Carpp LN, Shanks SG, Struthers MS, Bryant NJ.

Biochem Biophys Res Commun. 2007 Nov 23;363(3):857-60. Epub 2007 Sep 25.

PMID:
17904527
33.

Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.

Pinkerton AB, Huang D, Cube RV, Hutchinson JH, Struthers M, Ayala JM, Vicario PP, Patel SR, Wisniewski T, DeMartino JA, Vernier JM.

Bioorg Med Chem Lett. 2007 Feb 1;17(3):807-13. Epub 2006 Oct 25.

PMID:
17088058
34.

Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes.

Huang L, Zhao A, Wong F, Ayala JM, Struthers M, Ujjainwalla F, Wright SD, Springer MS, Evans J, Cui J.

Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1783-8. Epub 2004 Jul 22.

PMID:
15271789
35.
36.

Expression and characterization of the chemokine receptor CCR2B from rhesus monkey.

Jin H, Vicario PP, Zweerink H, Goyal S, Hanlon WA, Dorn CP, Mills SG, DeMartino JA, Cascieri MA, Struthers M.

Biochem Pharmacol. 2003 Jul 15;66(2):321-30.

PMID:
12826275
37.

THE PHYSICAL AND CHEMICAL MICROSTRUCTURE OF THE ACHATINA FULICA EPIPHRAGM.

Struthers M, Rosair G, Buckman J, Viney C.

J Molluscan Stud. 2002 May;68(2):165-171.

PMID:
12011243
38.

Peer Review. Can the Board of Medical Practice subpoena your files?

Mitchell LE, Bunde DP, Struthers MS, Wraspir KL, Moos RE.

Minn Med. 2000 Nov;83(11):55-6. No abstract available.

PMID:
11126484
39.

A single measurement of CD38CD8 cells in HIV+, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable.

Froebel KS, Raab GM, D'Alessandro C, Armitage MP, MacKenzie KM, Struthers M, Whitelaw JM, Yang S.

Clin Exp Immunol. 2000 Oct;122(1):72-8.

40.

G protein-coupled receptor activation: analysis of a highly constrained, "straitjacketed" rhodopsin.

Struthers M, Yu H, Oprian DD.

Biochemistry. 2000 Jul 11;39(27):7938-42.

PMID:
10891074
41.

Mapping tertiary contacts between amino acid residues within rhodopsin.

Struthers M, Oprian DD.

Methods Enzymol. 2000;315:130-43. No abstract available.

PMID:
10736699
42.

Tertiary interactions between the fifth and sixth transmembrane segments of rhodopsin.

Struthers M, Yu H, Kono M, Oprian DD.

Biochemistry. 1999 May 18;38(20):6597-603.

PMID:
10350478
43.

Design and NMR analyses of compact, independently folded BBA motifs.

Struthers M, Ottesen JJ, Imperiali B.

Fold Des. 1998;3(2):95-103.

44.

Is direct contracting the business of insurance?

Struthers MS, Anderson PD.

Minn Med. 1997 May;80(5):49-52. No abstract available.

PMID:
9164098
45.

The impact of the Americans with Disabilities Act on medical licensing and credentialing.

Struthers MS, Raphan M.

Minn Med. 1997 Jan;80(1):47-9. No abstract available.

PMID:
9009614
46.

An initial appraisal of the clinical significance of Roseomonas species associated with human infections.

Struthers M, Wong J, Janda JM.

Clin Infect Dis. 1996 Oct;23(4):729-33.

PMID:
8909835
47.

Physician recruitment by tax-exempt organizations.

Struthers MS, Zippel B.

Minn Med. 1996 Mar;79(3):47-51. No abstract available.

PMID:
8839069
48.

Design of a monomeric 23-residue polypeptide with defined tertiary structure.

Struthers MD, Cheng RP, Imperiali B.

Science. 1996 Jan 19;271(5247):342-5.

PMID:
8553067
49.

Laws prohibiting physician self-referrals. The impact on health care integration in Minnesota.

Struthers MS, Smith PJ.

Minn Med. 1996 Jan;79(1):29-32. No abstract available.

PMID:
8587557
50.

The medical futility debate continues.

Struthers MS, Olson BC.

Minn Med. 1995 Feb;78(2):29-32. No abstract available.

PMID:
7891646

Supplemental Content

Loading ...
Support Center